REAL-WORLD DOSING PATTERNS OF ECULIZUMAB-NAIVE AND ECULIZUMAB-EXPERIENCED PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA RECEIVING RAVULIZUMAB IN THE US

被引：0
|
作者：
Cheng, W. Y. [1 ]
Fishman, J. [2 ]
Yenikomshian, M. [1 ]
Mahendran, M. [1 ]
Kunzweiler, C. [1 ]
Vu, J. D. [1 ]
Duh, M. S. [1 ]
机构：
[1] Anal Grp Inc, Boston, MA USA
[2] Apellis Pharmaceut Inc, Waltham, MA USA
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
HSD77
引用
收藏
页码：S493 / S493
页数：1
相关论文
共 50 条
  • [41] Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition
    Roeth, Alexander
    He, Guangsheng
    Tong, Hongyan
    Lin, Zenghua
    Wang, Xiaoqin
    Chai-Adisaksopha, Chatree
    Lee, Je-Hwan
    Brodsky, Andres
    Hantaweepant, Chattree
    Dumagay, Teresita E.
    Demichelis-Gomez, Roberta
    Rojnuckarin, Ponlapat
    Sun, Jing
    Hoeglund, Martin
    Jang, Jun Ho
    Gaya, Anna
    Silva, Fernando
    Obara, Naoshi
    Kelly, Richard J.
    Beveridge, Leigh
    Buatois, Simon
    Chebon, Sammy
    Gentile, Brittany
    Lundberg, Pontus
    Sreckovic, Sasha
    Nishimura, Jun-ichi
    Risitano, Antonio
    Han, Bing
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2024, 99 (09) : 1768 - 1777
  • [42] Clinical and real-world pharmacovigilance data of meningococcal infections in eculizumab- or ravulizumab-treated patients
    Fam, Sami
    Werneburg, Brian
    Pandya, Shirali
    Parks, Becky
    Mashhoon, Yasmin
    Allen, Kerstin
    Frick, Glen
    Beasley, Katie
    Zodiatis, Alexander
    Chitikireddi, Vidya
    Zhang, Hua
    Sabatella, Guido
    Mujeebuddin, Arshad
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2023, 455
  • [43] Dosing Patterns of Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Ravulizumab in the United States: A Retrospective Claims-Based Analysis
    Wendy Y. Cheng
    Jesse Fishman
    Mihran Yenikomshian
    Malena Mahendran
    Colin Kunzweiler
    Jensen Duy Vu
    Mei Sheng Duh
    [J]. Advances in Therapy, 2024, 41 : 413 - 430
  • [44] Benefits and Limitations of Long-Term Eculizumab Treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH): Real-World Data from Large Cohort Study in Russia
    Kulagin, Aleksandr
    Klimova, Olesya
    Rudakova, Tatiana
    Golubovskaya, Irina
    Ivanova, Maria
    Smirnova, Anna
    Lapina, Alexandra
    Bykova, Tatiana
    Babenko, Elena
    Popova, Marina
    Dobronravov, Vladimir
    Afanasyev, Boris
    [J]. BLOOD, 2018, 132
  • [45] Dosing Patterns of Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Ravulizumab in the United States: A Retrospective Claims-Based Analysis
    Cheng, Wendy Y.
    Fishman, Jesse
    Yenikomshian, Mihran
    Mahendran, Malena
    Kunzweiler, Colin
    Vu, Jensen Duy
    Duh, Mei Sheng
    [J]. ADVANCES IN THERAPY, 2024, 41 (01) : 413 - 430
  • [46] Efficacy and Safety of Subcutaneous Ravulizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria Who Received Prior Intravenous Eculizumab: 2-Year Follow-up
    Piatek, Caroline I.
    de Fontbrune, Flore Sicre
    Sahin, Fahri
    Fuereder, Wolfgang
    Gualandro, Sandra Fatima
    Barcellini, Wilma
    Ogawa, Masayo
    Ortiz, Stephan
    Ozol-Godfrey, Ayca
    Szer, Jeff
    Yenerel, Mustafa
    [J]. BLOOD, 2023, 142
  • [47] Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria
    Scheinberg, Phillip
    Cle, Diego Villa
    Kim, Jin Seok
    Nur, Erfan
    Yenerel, Mustafa N.
    Barcellini, Wilma
    Bonito, Debora
    Giai, Valentina
    Hus, Marek
    Lee, Yoojin
    Lekue, Cristina Barrenetxea
    Panse, Jens
    Ueda, Yasutaka
    Buatois, Simon
    Gentile, Brittany
    Kiialainen, Anna
    Patel, Himika
    Sreckovic, Sasha
    Uguen, Marianne
    Edwards, John
    Nagy, Zsolt
    Kulasekararaj, Austin G.
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2024, 99 (09) : 1757 - 1767
  • [48] Eculizumab Dosing Intervals Longer than 17 Days May Be Associated with Greater Risk of Breakthrough Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria
    Nakayama, Hirokazu
    Usuki, Kensuke
    Echizen, Hirotoshi
    Ogawa, Ryuichi
    Orii, Takao
    [J]. BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2016, 39 (02) : 285 - 288
  • [49] Clinical Profile and Long-Term Outcomes of Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Eculizumab in a Real-World Setting: High Frequency of Anemia Despite Decreased Intravascular Hemolysis
    Versmold, Katharina
    Alashkar, Ferras
    Raiser, Carina
    Ofori-Asenso, Richard
    Xu, Tao
    Liu, Yutong
    Katz, Pablo
    Shang, Aijing
    Roeth, Alexander
    [J]. BLOOD, 2021, 138
  • [50] Clinical efficacy and safety of switching from eculizumab to ravulizumab in adult patients with aHUS- real-world data
    Schoenfelder, Kristina
    Kuehne, Lucas
    Schulte-Kemna, Lena
    Kaufeld, Jessica
    Rohn, Hana
    Kribben, Andreas
    Schroeppel, Bernd
    Brinkkoetter, Paul T.
    Gaeckler, Anja
    [J]. BMC NEPHROLOGY, 2024, 25 (01)
12345